Updated:
Mérieux Equity Partners
Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and...
Mérieux Equity Partners
Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. As an independent General Partner - registered under the French Financial Markets Authority AMF ("Autorité des Marchés Financiers") - Merieux Equity Partners currently manages 5 main funds, representing more than €1 billion of Commitments, and has supported over 45 companies in Europe and North America since its creation - in Venture Capital and Growth/Buyout. Our passion is to work alongside entrepreneurs and companies with an ambitious growth plan, offering them privileged access to our sector-expertise and cross-border experience. With a team of 24 full-time employees and 6 Senior Advisors, we strive to bring the best of our operational experience and privileged access to Merieux' industrial network.
General information
Firm type
Private Equity
Year founded
2009
AUM
€1.6bn+ (per firm website)
Location
Region
Europe
Country
France
City
Lyon
Corporate office
Lyon, France
Additional offices
Paris, France
Principals
Jean-François Billet
Managing Partner - Head of Buyout
Valérie Calenda
Managing Partner – Head of Innovation
Thierry Chignon
Managing Partner – Head of Investor Relations & Communication
Sector focus
Frequently asked questions
Who runs investment decisions at Mérieux Equity Partners?
The firm is led by three Managing Partners. Jean-François Billet heads the Buyout platform from Paris, Valérie Calenda leads the Innovation (venture) platform from Lyon, and Thierry Chignon oversees investor relations and communications. Each platform operates with dedicated investment teams and deal-level autonomy.
How does Mérieux Equity Partners source proprietary healthcare deals?
The firm draws on the Mérieux family's century-long network in diagnostics, biotech, and pharmaceuticals. This ecosystem includes bioMérieux and Institut Mérieux, generating scientific advisory relationships and corporate partnerships that surface deals before broad auction processes. The firm's position as a healthcare specialist — not a generalist — means entrepreneurs and intermediaries bring them sector-specific opportunities directly.
What is the relationship between Mérieux Equity Partners and the Mérieux family?
Mérieux Equity Partners manages third-party capital as an AMF-registered investment firm, but it was created in 2009 by the Mérieux family to institutionalize their healthcare-investment activity. The family's industrial holdings (notably bioMérieux) are separate entities. The equity platform benefits from the family's sector expertise and network without being a single-family office.
Does Mérieux Equity Partners invest outside Europe?
No. The firm's stated geographic mandate is strictly European. Confirmed investments are concentrated in France, Belgium, and the Nordics, with a demonstrated exit to an Italian acquirer (GTP Bioways to Olon Group, per firm website, July 2024).
What investment stages does Mérieux Equity Partners cover?
The firm covers the full spectrum from seed-stage venture to established-company buyouts through two distinct platforms. The Innovation platform writes €3m to €15m checks from seed to Series B, while the Buyout platform deploys €20m to €80m per deal into profitable, mid-sized healthcare companies. Co-investment capacity can increase the buyout check size.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: